Spiritual leader the Dalai Lama presents a framework for longevity biotechnology investments, urging ethical application, resource sustainability, and compassion-driven innovation. He emphasizes evaluating companies by ESG criteria and aligning anti-aging research with equitable access and ecological stewardship, providing investors a structured lens to balance scientific breakthroughs with moral responsibility.
Key points
ESG integration assesses environmental, social, and governance metrics in longevity biotech investing.
Investor interest in senolytics firms like Unity Biotechnology targeting aged cell clearance.
Sustainable innovations, including telepresence robotics and lab-grown organs, reduce resource strain.
Why it matters:
Integrating ethics and sustainability into longevity investments ensures capital fosters equitable, responsible anti-aging innovations that advance healthspan without compromising societal or environmental well-being.
Q&A
What does ESG mean in longevity investing?
How do senolytics combat aging?
What role does sustainability play in anti-aging startups?
Why emphasize compassionate innovation over immortality?
Read full article
Academy
ESG Screening in Longevity Biotechnology
Environmental, Social, and Governance (ESG) screening applies sustainability and ethics metrics to evaluate longevity biotech companies for responsible investing. ESG frameworks help investors assess the impact of research and products on ecosystems, communities, and transparent management practices to ensure long-term viability and social value.
- Environmental: resource efficiency, waste reduction, carbon footprint management
- Social: equitable access to therapies, community engagement, human dignity
- Governance: board independence, ethical leadership, transparency, regulatory compliance
By integrating ESG metrics, investors can prioritize companies that align innovation with sustainability and social justice, fostering a balance between advancing healthspan extension and preserving global resources.
Investors use ESG scores to compare different companies within the longevity sector. High ESG scores indicate companies that minimize environmental impact, proactively engage stakeholders, and maintain robust governance structures. For example, a biotech firm developing CRISPR-based gene therapies may score higher if it demonstrates transparent clinical trial reporting, equitable patient access programs, and sustainable laboratory practices.
Senolytics and Their Role in Anti-Aging
Senolytics are compounds designed to selectively clear senescent cells that accumulate with age and contribute to tissue dysfunction. Removing these "zombie" cells can rejuvenate tissues, improve organ function, and reduce age-related inflammation, offering a promising avenue for healthspan extension.
Key principles:
- Identification of senescent cells using biomarkers such as p16INK4a and SASP factors.
- Selective targeting through small molecules like BCL-2 inhibitors or peptides that induce apoptosis in senescent cells.
- Delivery methods including nanoparticles, liposomes, or engineered peptides for tissue-specific action.
Clinical trials of senolytic agents, such as dasatinib and quercetin combinations, have shown preliminary improvements in physical function in older adults. Researchers are also exploring next-generation senolytics targeting specific cell types to maximize therapeutic benefits while reducing off-target effects. Integrating biomarkers and imaging techniques enables monitoring of senescent cell clearance and tissue regeneration outcomes.